Phibro Animal Health Corporation $PAHC Shares Sold by Walleye Capital LLC

Walleye Capital LLC decreased its holdings in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 58.1% in the first quarter, Holdings Channel.com reports. The institutional investor owned 27,755 shares of the company’s stock after selling 38,436 shares during the quarter. Walleye Capital LLC’s holdings in Phibro Animal Health were worth $1,535,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. KBC Group NV acquired a new position in Phibro Animal Health during the first quarter worth about $29,000. 1620 Investment Advisors Inc. raised its holdings in Phibro Animal Health by 77.4% in the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after acquiring an additional 295 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in Phibro Animal Health by 113.2% in the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock valued at $27,000 after acquiring an additional 386 shares during the last quarter. Rothschild Investment LLC lifted its stake in Phibro Animal Health by 2,500.0% in the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock worth $39,000 after purchasing an additional 1,000 shares in the last quarter. Finally, iSAM Funds UK Ltd purchased a new position in Phibro Animal Health in the 3rd quarter worth approximately $61,000. 99.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PAHC has been the topic of several recent research reports. Zacks Research cut Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st. Citigroup cut their price target on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a report on Thursday, May 14th. Weiss Ratings downgraded Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, June 15th. Finally, Wall Street Zen lowered Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. One analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $42.50.

Phibro Animal Health Price Performance

Shares of PAHC stock opened at $34.04 on Friday. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26. The company has a market capitalization of $1.38 billion, a PE ratio of 14.61, a price-to-earnings-growth ratio of 0.47 and a beta of 0.46. The firm’s 50-day moving average is $32.46 and its two-hundred day moving average is $43.32. Phibro Animal Health Corporation has a 12 month low of $25.58 and a 12 month high of $60.08.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.04. The business had revenue of $383.54 million during the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Analysts predict that Phibro Animal Health Corporation will post 3.08 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 24th. Investors of record on Wednesday, June 3rd were given a $0.12 dividend. This represents a $0.48 annualized dividend and a yield of 1.4%. The ex-dividend date was Wednesday, June 3rd. Phibro Animal Health’s dividend payout ratio is presently 20.60%.

Insiders Place Their Bets

In other Phibro Animal Health news, CEO Jack Bendheim sold 7,040 shares of the firm’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $55.80, for a total transaction of $392,832.00. Following the completion of the sale, the chief executive officer owned 67,720 shares of the company’s stock, valued at $3,778,776. This trade represents a 9.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 25,648 shares of company stock valued at $1,377,432 in the last ninety days. Corporate insiders own 50.13% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.